ASH 2017 | Exciting novel AML treatment: venetoclax plus cobimetinib or idasanutlin in elderly patients
Venetoclax combinations have shown excellent results in chronic lymphocytic leukemia (CLL), but are now, excitingly, displaying fantastic preliminary outcomes in acute lymphocytic leukemia (ALL). In this interview, Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of the Phase Ib study (NCT02670044), which is now moving into Phase II. Dr Daver highlights how the trial was in elderly patients with R/R AML, which is arguably the highest risk group, and has still shown promising durable response rates. He then discusses the next stage of testing, including the dose and possible addition of a hypomethylating backbone agent. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Get great new content delivered to your inboxSign up